Teladoc Inc (NYSE:TDOC) CFO Mark Hirschhorn sold 30,000 shares of Teladoc stock in a transaction dated Monday, December 4th. The stock was sold at an average price of $32.99, for a total value of $989,700.00. Following the completion of the transaction, the chief financial officer now owns 5,203 shares of the company’s stock, valued at $171,646.97. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Mark Hirschhorn also recently made the following trade(s):

  • On Monday, October 16th, Mark Hirschhorn sold 25,000 shares of Teladoc stock. The stock was sold at an average price of $32.37, for a total value of $809,250.00.
  • On Tuesday, October 17th, Mark Hirschhorn sold 35,000 shares of Teladoc stock. The stock was sold at an average price of $32.84, for a total value of $1,149,400.00.
  • On Monday, October 2nd, Mark Hirschhorn sold 10,000 shares of Teladoc stock. The stock was sold at an average price of $34.04, for a total value of $340,400.00.
  • On Friday, September 22nd, Mark Hirschhorn sold 25,000 shares of Teladoc stock. The shares were sold at an average price of $31.93, for a total value of $798,250.00.

Teladoc Inc (NYSE TDOC) opened at $31.50 on Thursday. Teladoc Inc has a twelve month low of $15.65 and a twelve month high of $37.90. The company has a debt-to-equity ratio of 0.83, a quick ratio of 5.08 and a current ratio of 5.08.

Teladoc (NYSE:TDOC) last posted its quarterly earnings data on Wednesday, November 1st. The health services provider reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.25). Teladoc had a negative return on equity of 29.70% and a negative net margin of 45.64%. The firm had revenue of $68.70 million for the quarter, compared to analysts’ expectations of $67.53 million. During the same quarter in the previous year, the firm posted ($0.33) earnings per share. The company’s revenue for the quarter was up 112.0% on a year-over-year basis. research analysts anticipate that Teladoc Inc will post -1.57 EPS for the current year.

A number of brokerages have commented on TDOC. Robert W. Baird downgraded Teladoc from an “outperform” rating to a “neutral” rating and lifted their target price for the company from $14.00 to $36.00 in a research note on Monday, September 18th. KeyCorp restated a “buy” rating and issued a $37.00 target price on shares of Teladoc in a research note on Sunday, September 17th. Zacks Investment Research upgraded Teladoc from a “sell” rating to a “buy” rating and set a $38.00 target price for the company in a research note on Wednesday, October 4th. Cowen restated an “outperform” rating and issued a $39.00 target price on shares of Teladoc in a research note on Saturday, September 30th. Finally, BidaskClub upgraded Teladoc from a “sell” rating to a “hold” rating in a research note on Wednesday, September 6th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and nine have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $39.17.

Several hedge funds have recently added to or reduced their stakes in the stock. ETF Managers Group LLC acquired a new position in shares of Teladoc during the second quarter valued at about $104,000. Bank of Montreal Can increased its stake in Teladoc by 214.2% in the second quarter. Bank of Montreal Can now owns 3,516 shares of the health services provider’s stock valued at $123,000 after acquiring an additional 2,397 shares during the period. Pacad Investment Ltd. bought a new stake in Teladoc during the second quarter worth about $135,000. Fred Alger Management Inc. bought a new stake in Teladoc during the second quarter worth about $139,000. Finally, Legal & General Group Plc grew its stake in Teladoc by 66.3% during the first quarter. Legal & General Group Plc now owns 6,137 shares of the health services provider’s stock worth $154,000 after buying an additional 2,446 shares during the last quarter.

TRADEMARK VIOLATION WARNING: This report was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The original version of this report can be viewed at https://www.thecerbatgem.com/2017/12/07/teladoc-inc-tdoc-cfo-sells-989700-00-in-stock.html.

Teladoc Company Profile

Teladoc, Inc is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company’s solution connects its Members, with its over 3,000 board certified physicians and behavioral health professionals treating a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation.

Insider Buying and Selling by Quarter for Teladoc (NYSE:TDOC)

Receive News & Ratings for Teladoc Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Inc and related companies with MarketBeat.com's FREE daily email newsletter.